The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Glenmark will begin distribution in November 2025
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
From material selection to cooling tower management, every small decision affects long-term equipment reliability
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
_256_384.jpg)
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Subscribe To Our Newsletter & Stay Updated
